April 3 (Reuters) - Regeneron Pharmaceuticals Inc:
* EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA
* EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED FOR REVIEW AN APPLICATION FOR DUPIXENT Source text for Eikon: Further company coverage: